Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : Walmart launches low-priced private label analog insulin

06/29/2021 | 08:25am EDT
FILE PHOTO: The logo of Walmart is seen on shopping trolleys at their store in Sao Paulo

CHICAGO (Reuters) - Walmart said on Tuesday that it will start selling private-label analog insulin this week at a deep discount to branded insulin vials and pens, as it seeks to drive growth at its healthcare business.

The product, ReliOn NovoLog, is a rapid-acting analog insulin used to control high blood sugar in adults and children with diabetes. It will require a prescription from a physician. More than two decades ago, Walmart launched a human insulin private label brand called ReliOn that costs $24.99 a vial.

The world's largest retailer said its more than 3 million customers with diabetes could save between 58% and 75% off the cash price of branded analog insulin products, or up to $101 per branded vial or $251 per package of branded FlexPen.

Analog insulin tends to be more effective and easier to administer than the older, human insulin.

About one in 10 Americans have diabetes, or roughly 34 million people. The vast majority have type 2 diabetes, a chronic condition linked to genetics, along with weight gain and inactivity. Diet and exercise can help manage the disease, but some patients also need insulin or other medication.

Alternatively, about 1.2 million people have type 1 diabetes, an autoimmune disease that requires lifelong insulin injections after the pancreas stops producing a sufficient amount.

For years, patients, consumer advocates and U.S. lawmakers have complained about the high list prices for insulin and the significant out-of-pocket costs borne by patients.

Walmart, which is working with pharmaceutical company Novo Nordisk, said its products were intended for use by patients with both type 1 and type 2 diabetes.

Bentonville, Arkansas-based Walmart has for years strategically lowered consumer prices for generic drugs, undercutting branded products sold by other retailers.

    In 2006, Walmart began selling some generic drugs for $4 per monthly prescription - a tactic soon adopted by a number of pharmacy operators.

(Reporting by Richa Naidu; Additional reporting by Chad Terhune in Los Angeles; Editing by Stephen Coates)

By Richa Naidu

© Reuters 2021
All news about NOVO NORDISK A/S
09/16VC DAILY : Venture Capitalists Push Back Against -2-
09/14ANALYST RECOMMENDATIONS : Apple, Bank of America, Cisco, DT Midstream, Halliburt..
09/14NOVO NORDISK : Jefferies reiterates its Sell rating
09/13NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
09/07NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
09/06NOVO NORDISK A/S : – Share repurchase programme
09/02NOVO NORDISK : Berenberg reaffirms its Neutral rating
09/02ANALYST RECOMMENDATIONS : AstraZeneca, Designer Brands, Homeserve, Rio Tinto, Tr..
09/01NOVO NORDISK : Buy rating from Deutsche Bank
08/31NOVO NORDISK A/S : MIT - Drug delivery capsule could replace injections for prot..
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Sales 2021 137 B 21 611 M 21 611 M
Net income 2021 46 384 M 7 316 M 7 316 M
Net cash 2021 6 198 M 978 M 978 M
P/E ratio 2021 32,0x
Yield 2021 1,55%
Capitalization 1 474 B 233 B 232 B
EV / Sales 2021 10,7x
EV / Sales 2022 9,70x
Nbr of Employees 45 971
Free-Float 69,8%
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Last Close Price 643,40 DKK
Average target price 604,48 DKK
Spread / Average Target -6,05%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S50.80%232 556
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
ABBVIE INC.0.54%190 378